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A B S T R A C T
Fusobacterium necrophorum is a non-spore-forming, obligate anaerobic, ﬁlamentous, gramnegative
bacillus that frequently colonizes the human oral cavity, respiratory tract, and gastrointestinal tract.
Fusobacterium species have rarely been implicated in cases of gastrointestinal variant of Lemierre’s
syndrome. We describe a case of F. necrophorum bacteremia associated with suppurative porto-
mesenteric vein thrombosis (PVT) following acute ruptured appendicitis. In addition, we list the
documented twelve cases of Fusobacterium pylephlebitis. Recanalization of the porto-mesenteric veins
and relief of the extrahepatic portal hypertension were achieved with early empiric antibiotic and local
thrombolytic therapy. Our patient’s case underscores the importance of recognizing Fusobacterium
bacteremia as a possible cause of suppurative PVT after disruption of the gastrointestinal mucosa
following an acute intraabdominal infectious process. Early treatment of this condition using
anticoagulation and endovascular thrombolysis as adjunctive therapies may prevent PVT complications.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fusobacteria are non-sporulating, obligate anaerobic, ﬁlamen-
tous, gram-negative bacilli belonging to the Bacteroidaceae family.
They are constituents of the normal ﬂora of the oropharynx, the
female genitourinary tract and the gastrointestinal tract [1,2].
Fusobacterium species have traditionally been associated with
Lemierre’s syndrome (LS), a potentially fatal complication of head
and neck infections, which is characterized by septic thrombo-
phlebitis of the internal jugular vein (IJV) and/or its tributaries (e.g.
facial vein) [1,2]. Thrombus formation and rapid bacterial growth
can cause septic embolization to distant sites including the lungs,
joints, bones, skin and soft tissues, muscles, liver, spleen, kidneys,
heart, and brain [3]. Moreover, variants of Lemierre’s syndrome
have been described in multiple anatomic locations such as the
cavernous sinus, ovarian veins, suprahepatic veins, and the porto-
mesenteric venous system [2]. Fusobacterium species have been
linked to porto-mesenteric vein thrombosis (PVT) in at least twelve
reports (Table 1), with two-third of the cases possibly propagating
from the lower gastrointestinal tract (GIT). We report a rare case of* Corresponding author at: Department of Infectious Diseases, Infection Control
and Employee Health, Pikeville Medical Center, 911 Bypass Road, Pikeville, KY
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4.0/).portal, splenic and mesenteric vein thrombosis associated with
Fusobacterium necrophorum following acute ruptured appendicitis.
No oropharyngeal involvement was identiﬁed to suggest the
classic form of LS. To our knowledge, this is the ﬁrst reported case
linking Fusobacteria to PVT with a simultaneous documented
intra-abdominal source. This case also illustrates the potential
beneﬁts of anticoagulation and endovascular thrombolysis as
adjunctive therapies in prevention of PVT complications.
Case presentation
A previously healthy 32-year-old Caucasian male initially
presented with a two day-history of worsening epigastric pain.
He was diagnosed with a ruptured appendicitis and required
emergent laparoscopic appendectomy. Following the procedure he
was discharged home but continued to have fevers and abdominal
pain. One week later, he returned to the emergency department
with severe, worsening right upper quadrant epigastric pain
radiating to the back without guarding, rebound tenderness or
abdominal ecchymosis. He denied alcohol or recreational drug use
and could provide no preceding history suggestive of oropharyn-
geal or respiratory tract infection. Upon examination the patient
was found to be in septic shock (temperature 103 8F, pulse
108 beats/minute and mean arterial pressure of 47 mmHg). Oral,
neck, respiratory, cardiovascular and neurological examinations
were unremarkable. He was transferred to the medical intensivee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Table 1
Porto-mesenteric vein thrombosis associated with Fusobacterium species.
References Patient
age (y), sex
Past medical
history
Infection source Anticoagulation Antibiotic therapy Outcome Workup for
Lemierre’s
syndrome
Underlying
coagulation
disorder
Reported cases of pylephlebitis caused Fusobacterium necrophorum
Current case (2014) 34, M Previously healthy Acute perforated
appendicitis
Local thrombolysis
and IV heparin
Pip/taz followed by
clindamycin
Survived and clinically
improved. Portal cavernous
sinus formation
Negative Negative
Hamidi K,
et al. (2008)
23, M Previously healthy No abdominal
infectious focus
LMWH followed by
ﬂuindione
AM/CL Survived and clinically
improved. Portal cavernous
sinus formation
Not performed Negative
41, M Alcoholism No abdominal
infectious focus
No No Loss of follow up. Left the
hospital against medical advice
Not performed Not done
Soo R, et al. (1999) 31, M Previously healthy No identiﬁed
abdominal
infectious focus
IV heparin followed
by warfarin
IV metronidazole
and Penicillin G
followed by AM/CL
and metronidazole
LFTs normalized over 6 months Not performed Negative
Shahani L, et al. (2011) 34, M Chronic pancreatitis
and alcoholism
Hepatic, pancreatic
and splenic
abscesses
No Tigecycline Clinically improved. Resolution
of liver abscesses with portal
cavernous transformation
Negative Was not
considered
Clarke MG, et al. (2003) 19, F Previously healthy Hepatic abscesses IV heparin followed
by long term
warfarin
Benzyl Penicillin,
metronidazole and
ciproﬂoxacin
Clinically improved. Resolution
of liver abscesses and portal
cavernous sinus transformation
Not performed Was not
considered
Redford MR, et al. (2005) 53, M Previously healthy No abdominal
infectious focus
LMWH followed by
warfarin
Benzyl PCN and
metronidazole
followed by
clindamycin
The patient made a complete
clinical recovery
Not performed Was not
considered
Reported cases of pylephlebitis caused Fusobacterium nucleatum
Bultink IE, et al. (1999) 23, M Previously healthy Possible
pharyngitis. No
abdominal focus
IV heparin Imipenem followed
by 6 weeks of IV
PCN
Patient had clinical recovery but
portal vein thrombosis persisted
Not performed Negative
Zheng L, et al. (2014) 73, M HTN, DM, CAD No oropharyngeal
or abdominal focus
LMWH followed by
warfarin
Cefepime followed
by clindamycin
The patient made a complete
clinical recovery
Negative Negative
Verna EC, et al. (2004) 56, M Ulcerative colitis No oropharyngeal
or abdominal focus
No Clindamycin for
2 weeks
Patient had clinical recovery but
portal vein thrombosis persisted
Negative Elevated
serum
factor VIII
El Braks R, et al. (2004) 71, F Urinary continence Pharyngitis. No
abdominal focus
IV heparin Pip/taz for 2 weeks
followed by
oﬂoxacin for
additional 3 weeks
Patient had clinical recovery but
left branch portal vein
thrombosis persisted
Not performed Negative
Etienne M, et al. (2001) 68, M Lung and GU TB,
thrombocytopenia,
recurrent PE, and IVC ﬁlter
Possible
oropharyngeal
source. No
abdominal focus
LMWH for 24 days Cefotaxime and
metronidazole for
24 days followed by
2 weeks of oral
metronidazole
Patient had clinical and
radiological recovery
Not performed Negative
Schweigart JH,
et al. (2005)
67, M TB, stroke, DM, Aﬁb,
CKD and IgG
paraproteinemia
Possible
oropharyngeal
source. No
abdominal focus
Long-termwarfarin Clindamycin Clinically improved Not performed Negative
Abbreviations: Aﬁb; atrial ﬁbrillation, AM/CL; amoxicillin/clavulanate, CAD; coronary artery disease, CKD; chronic kidney disease, DM; diabetes mellitus, F; female, GU; genitourinary, HTN; hypertension, IV; intravenous, IVC;
inferior vena cava, LFTs; liver function tests, LMWH; low-molecular weight heparin, M; male, PCN; penicillin, PE; pulmonary embolism, Pip/taz; piperacillin/tazobactam, TB; tuberculosis.
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Fig. 1. A computerized axial tomography (CAT scan) of the abdomen and pelvis with intravenous contrast and ultrasound Doppler studies showed splenomegaly with acute
thrombosis of the proximal main portal vein at the conﬂuence of the superior mesenteric vein (SMV) and splenic vein. No hepatic abnormalities were identiﬁed to suggest
cirrhosis, infarct, abscess or cavernous transformation.
F.A. Akhrass et al. / IDCases 2 (2015) 72–7674care unit and received aggressive ﬂuid resuscitation, vasopressors
and initiation of broad coverage antibiotics with vancomycin and
piperacillin/tazobactam. Laboratory investigations showed an
elevated white blood cell count of 15,100 cells/mm [3], with an
absolute neutrophil count of 12,400 cells/mm [3]. Platelet count,
hemoglobin, electrolytes, renal function, pancreatic enzymes and
liver function tests were all within the normal range. Urine drug
screen, blood alcohol test, HIV ELISA and viral hepatitis proﬁle
were also negative. A computerized axial tomography (CAT scan)
of the abdomen and pelvis with intravenous contrast and
ultrasound Doppler studies showed splenomegaly with acute
thrombosis of the proximal main portal vein at the conﬂuence of
the superior mesenteric vein (SMV) and splenic vein (Fig. 1). No
hepatic abnormalities were identiﬁed to suggest cirrhosis, infarct,
abscess or cavernous transformation. Comprehensive hypercoag-
ulability workup was negative. Interestingly, the anaerobic bottlesFig. 2. Venography revealed the presence of cavernous transformation of the
portal vein.of two sets of blood cultures taken on admission yielded thin
ﬁlamentous gram negative bacilli, eventually identiﬁed as F.
necrophorum on day six of the admission. CAT-scans of the head,
neck and chest showed no evidence of any brain, pulmonary or
cervical (including the IJV) involvement. The gastrointestinal
variant of Lemierre’s syndrome was thus diagnosed. Following the
identiﬁcation of F. necrophorum, vancomycin was discontinued and
metronidazole was added to the regimen. The patient was
anticoagulated with intravenous heparin, but the patient’s
abdominal pain persisted and the thrombus continued to progress
on subsequent imaging. At this point, venography revealed the
presence of cavernous transformation of the portal vein (Fig. 2).
Transhepatic endovascular thrombolysis was attempted to miti-
gate the thrombotic disease, and was successful in recanalizing the
porto-mesenteric veins (Fig. 3). The patient was discharged home
on warfarin and oral clindamycin for six more weeks leading to
complete symptom relief.
Discussion
Pylephlebitis, deﬁned as septic thrombophlebitis of the portal
vein and/or its tributaries, has rarely been reported in the modern
era of antibiotics [4]. Its diagnosis hinges on positive culture data inFig. 3. Transhepatic endovascular thrombolysis was attempted to mitigate the
thrombotic disease, and was successful in recanalizing the porto-mesenteric veins.
F.A. Akhrass et al. / IDCases 2 (2015) 72–76 75conjunction with radiological evidence of acute thrombosis of the
portal vein. This complication can occur secondary to any
abdominal or pelvic suppuration either in the regions drained
by the portal system or in structures contiguous to the portal vein,
typically appendicitis or diverticulitis [4]. Early diagnosis with
prompt medical and surgical treatment may reduce the incidence
of ascending portal septic thrombophlebitis to 0.05% in acute
appendicitis and 3% in ruptured appendix [5]. Liver abscesses and
bowel ischemia are known acute complications of pylephlebitis,
and portal hypertension is a possible chronic sequela [2]. Enteric
gram-negative bacilli and anaerobes, most notably Bacteroides
fragilis, are common organisms associated with pylephlebitis, with
concomitant bacteremia seen in up to 80% of cases [6]. Isolated
cases of pylephlebitis associated with Fusobacterium species
have been described but none of these patients had an identiﬁable
infectious GIT source (Table 1). Four cases of pylephlebitis have
been linked to Fusobacterium nucleatum LS. One theory is that
following oropharyngeal infection, septic emboli to the mesentery
can cause contiguous microabscesses to the GIT (e.g. lymphadeni-
tis) with subsequent spread to the porto-mesenteric venous
system. Another hypothesis is bacterial seeding of preexisting
portal thrombosis. Other cases of reported fusobacterial pylephle-
bitis had no discernible site of entry, and appear to be due to
subclinical primary infection affecting the lower GIT. In the patient
we describe, the source of the pathogen was most likely the
appendix, where F. necrophorum is a known part of the commensal
anaerobic colonic ﬂora and is further known to play an important
role in the pathogenesis of appendicitis [7]. The exact pathogenesis
of pylephlebitis related to F. necrophorum is unknown, but several
mechanisms have been proposed. Following disruption of the
mucosal appendiceal architecture, the organism can enter the
venous system via the appendicular vein, eventually draining to
the ileocolic vasculature, the superior mesenteric vein and then
to the portal vein [8]. Alternatively, the organism could invade
the periappendicular tissues, causing perivenous inﬂammation
(periphlebitis) and luminal thrombosis (endophlebitis). The
thrombogenic ability of virulent Fusobacterium strains has also
been attributed to the lipid A component of the lipopolysaccharide
(LPS) endotoxin, which activates the human Hageman factor
(factor XII) and thereby the intrinsic pathway of coagulation
[9]. Furthermore, these strains can also increase leucotoxin
production resulting in activation and aggregation of human
platelets [10]. The fusobacterial thrombogenic activity and locally
generated proteolysis allow tissue damage, penetration through
host barriers, and invasion of regional veins, thereby causing
serious infections. These bacterial characteristics appear to favor
direct porto-mesenteric invasion as the mode of pathogenesis
of pylephlebitis, rather than seeding pre-existing thrombus.
Imaging techniques such as ultrasound and contrast-enhanced
CT scan are the diagnostic tools of choice for PVT. Ultrasound is
especially helpful because of its accuracy, non-invasiveness,
and low cost. There is also evidence that this modality has an
acceptable sensitivity and speciﬁcity for the diagnosis of appendi-
citis or appendiceal masses with adequate training [11]. Nonethe-
less, contrast-enhanced CT scan has the advantage of better
sensitivity and speciﬁcity over ultrasound, particularly when
establishing extent of thrombus and for evaluation of solid organ
abnormalities, such as liver abscesses [12].
A multidisciplinary approach is needed to treat patients with
pylephlebitis to achieve the best therapeutic outcome. Treatment
involves the use of appropriate antibiotics and surgical drainage of
the primary suppurative focus. Despite prompt and appropriate
antimicrobial treatment, clinical response and defervescence in
patients with the gastrointestinal variant of LS might be delayed.
This could be related to the difﬁculty in adequate antimicrobial
penetration into the infected thrombus. Additionally, antibioticsare slow to sterilize the original infected, necrotic source, which
may allow persistent fevers. For these reasons, prolonged
antibiotic therapy is often required (usually 4–6 weeks) but ideal
duration of therapy remains unclear [13]. Antibiotics should be
tailored according to the culture and susceptibility data when
available. Usually, F. necrophorum is sensitive in vitro to penicillin/
beta-lactamase inhibitor combinations, metronidazole, cephalos-
porins, chloramphenicol, carbapenems, and clindamycin [14].
Antimicrobial resistance among F. necrophorum is rare. A review of
100 F. necrophorum isolates from 1990 to 2000 revealed that only
2% of strains were resistant to penicillin, and 15% were resistant to
erythromycin [14]. Metronidazole has excellent penetration into
most tissue including the central nervous system, and can be given
orally without sacriﬁcing bioavailability [15]. The beneﬁt of
adjunctive anti-coagulation to achieve recanalization of occluded
porto-mesenteric venous system has yet to be clearly demonstrat-
ed. Nevertheless, its use has been advocated on the presumption
that pylephlebitis might lead to bowel compromise and ischemia
[6]. Furthermore, anti-coagulation may reduce septic embolization
to the liver from infected portal thrombi and prevents liver
abscesses. Indications for anti-coagulation include documented
progression of thrombus while on antibiotics, fever unresponsive
to treatment and the presence of a hypercoagulable state [16].
Radiological or operative interventions in the form of thrombect-
omy and thrombolysis with direct intra-vascular infusion of
thrombolytics have been advocated for pylephlebitis with
peritoneal signs or enteric compromise [17,18]. Three main routes
of endovascular therapy for mesenteric thrombus have been
described: trans-arterial, trans-jugular and trans-hepatic. All three
techniques involve the slow infusion of tissue plasminogen activator
(tPA). Other endovascular techniques such as thrombectomy,
angioplasty and stenting can be performed adjunctively. Regardless
of the endovascular method selected, available data from small
studies seem to support the use of thrombolysis in the setting
of acute symptomatic porto-mesenteric vein thrombus [19,20].
Conclusion
Fusobacterium species are classically associated with LS but
have infrequently been implicated in clinical cases of pylephlebitis
[2]. Our review of the medical literature revealed only twelve
previously documented cases (Table 1). We believe that fusobac-
terial pylephlebitis has been historically underdiagnosed, as
culprit anaerobic gram-negative organisms could not previously
be reliably identiﬁed. The comparatively unsophisticated anaero-
bic culture methods of the past may have led to misattributed
causation by other organisms and, as F. necrophorum has
historically been known by more than 50 names, confusion with
nomenclature may have confounded identiﬁcation [2]. The results
of our patient’s history, physical examination, blood cultures and
imaging studies were consistent with the gastrointestinal variant
of LS. Furthermore, based on the pathophysiology of the organism
and the patient’s recent acute appendicitis, it appears reasonable to
implicate the appendix as the source of the pylephlebitis. Because
of possible resistance to several antibiotic classes, Fusobacterium
bacteremia is best treated empirically by means of combination
therapy until ﬁnal susceptibility results are available. This case
underscores the importance of recognizing Fusobacterium species as
a possible cause of pylephlebitis. As the consequences of untreated
PVT could be debilitating, we additionally suggest the use of
anticoagulation and consideration of endovascular thrombolysis, in
the setting of acute symptomatic porto-mesenteric vein thrombus.
Funding
None.
F.A. Akhrass et al. / IDCases 2 (2015) 72–7676Conﬂicts of interest
All authors declare that they have no conﬂicts of interest.
Authorship statement
All work in this manuscript is original. All authors had access to
the data and played a role in writing the manuscript. Each accepts
responsibility for the content.
Consent
Written informed consent was obtained from the patient for
publication of this case report. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
References
[1] Lemierre A. On certain septicemias due to anaerobic organisms. Lancet
1936;227:701–3.
[2] Riordan T. Human infection with Fusobacterium necrophorum (Necrobacillo-
sis), with a focus on Lemierre’s syndrome. Clin Microbiol Rev 2007;20:622–59.
[3] Chirinos JA, Lichtstein DM, Garcia J, Tamariz LJ. The evolution of Lemierre
syndrome: report of 2 cases and review of the literature. Medicine (Baltimore)
2002;81:458–65.
[4] Daly JM, Adams JT, Fantini GA, Fischer JE. Abdominal wall, omentum, mesen-
tery, and retroperitoneum. In: Schwartz SI, et al., editors. 7th ed., Principles of
surgery, vol. 2, 7th ed. New York: McGraw-Hill; 1999. p. 1572 [chapter 13].
[5] Scwartz SJ, Shires GT, Spencer FC, Husser WC. Principles of surgery. 6th ed.
New York: McGraw-Hill; 1994. 1327.[6] Plemmons RM, Dooley DP, Longﬁeld RN. Septic thrombophlebitis of the portal
vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect
Dis 1995;21:1114–20.
[7] Swidsinski A, Do¨rffel Y, Loening-Baucke V, Theissig F, Ru¨ckert JC, Ismail M, et al.
Acute appendicitis is characterized by local invasion with Fusobacterium
nucleatum/necrophorum. Gut 2011;60:34–40.
[8] Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, patho-
genesis and management. J Hepatol 2000;32:865–71.
[9] Bjornson HS. Activation of Hageman factor by lipopolysaccharides of Bacter-
oides fragilis, Bacteroides vulgatus and Fusobacterium mortiferum. Rev Infect Dis
1984;6:30–3.
[10] Forrester LJ, Campbell BJ, Berg JN, Barrett JT. Aggregation of platelets by
Fusobacterium necrophorum. J Clin Microbiol 1985;22:245–9.
[11] Sirit CJ. Diagnosis of acute appendicitis in children: spectrum of sonographic
ﬁndings. Am J Radiol 1993;161:147–52.
[12] Balthazar EJ, Gollapudi P. Septic thrombophlebitis of the mesenteric and portal
veins: CT imaging. J Comput Assist Tomogr 2000;24:755–60.
[13] Gosbell I, Gallo J, Pokorny CS. Septic portal vein thrombosis due to Fusobacter-
ium necrophorum. Aust N Z J Med 1999;29:569–70.
[14] Brazier JS, Hall V, Yusuf E, Duerden BI. Fusobacterium necrophorum infections in
England and Wales 1990–2000. J Med Microbiol 2002;51:269–72.
[15] Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and
update. Drugs 1997;54:679–708.
[16] Baril N, Wren S, Radin R, Ralls P, Stain S. The role of anticoagulation in
pyelophlebitis. Am J Surg 1996;172:449–53.
[17] Kaplan JL, Weintraub SL, Hunt JP, Gonzalez A, Lopera J, Brazzini A. Treatment of
superior mesenteric and portal vein thrombosis with direct thrombolytic
infusion via operatively placed mesenteric catheter. Am Surg 2004;70:600–4.
[18] Nishimori H, Ezoe E, Ura H, Imaizumi H, Meguro M, Furuhata T, et al. Septic
thrombophlebitis of the portal and superior mesenteric veins as a complica-
tion of appendicitis: report of a case. Surg Today 2004;34:173–6.
[19] Hedayati N, Riha GM, Kougias P, Huynh TT, Cheng C, Bechara C, et al. Prognostic
factors and treatment outcome in mesenteric vein thrombosis. Vasc Endo-
vascular Surg 2008;42:217–24.
[20] Cenedese A, Monneuse O, Gruner L, Tissot E, Mennesson N, Barth X. Initial
management of extensive mesenteric venous thrombosis: retrospective study
of nine cases. World J Surg 2009;33:2203–8.
